. 2022 Jun 9;9:905085. doi: 10.3389/fmed.2022.905085

TABLE 6.

Weighted odds ratios (95% confidence intervals) for hyperinsulinemia of participants across quartiles of serum uric acid (Men = 2,498, women = 2,650).

	Case/Participants	Crude^a	Model 1^a	Model 2^a
Men^†
Q1	635/2,498	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
Q2	685/2,498	1.5 (1.0–2.2) ^*	1.5 (1.0–2.2) ^*	1.2 (0.7–1.9)
Q3	567/2,498	2.8 (1.8–4.3) ^**	2.8 (1.8–4.3) ^**	1.6 (0.9–2.9)
Q4	611/2,498	4.4 (3.1–6.3) ^**	4.5 (3.1–6.5) ^**	1.8 (1.1–2.8) ^*
Women^†
Q1	663/2,650	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
Q2	694/2,650	1.7 (1.2–2.4) ^**	1.8 (1.3–2.6) ^**	1.3 (0.7–2.4)
Q3	648/2,650	2.3 (1.5–3.5) ^**	2.4 (1.5–3.8) ^**	1.3 (0.7–2.4)
Q4	645/2,650	5.4 (3.6–8.0) ^**	5.9 (4.0–8.9) ^**	2.0 (1.1–3.8) ^*

^aCalculated using binary logistic regression.

^†Men: Q1 (uric acid ≤ 309.30 μmol/L), Q2 (309.30 < uric acid ≤ 356.90 μmol/L), Q3 (356.90 < uric acid ≤ 404.50 μmol/L), and Q4 (uric acid > 404.50 μmol/L). Women: Q1 (uric acid ≤ 232.00 μmol/L), Q2 (232.00 < uric acid ≤ 273.60 μmol/L), Q3 (273.60 < uric acid ≤ 321.20 μmol/L), and Q4 (uric acid > 321.20 μmol/L).

Model 1 adjusted for race.

Model 2 adjusted for race, body mass index, waist circumference, drinking status, education level, hypertension, serum triglyceride, total cholesterol, and urate-lowering therapy.

*P < 0.05.

**P < 0.01.